BTK and leukemia: Consequently, Btk inhibition leads to the interruption of many down-stream cell signaling pathways related to the development of B cell malignancies (e.g., different types of leukemias and lymphomas) [8] and autoimmune diseases (e.g., rheumatoid arthritis, RA, and multiple sclerosis, MS) [9].